| Q90365685 | A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication |
| Q39027283 | A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids |
| Q39434224 | A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma |
| Q33414357 | A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma |
| Q59132458 | A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205) |
| Q42599445 | A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report |
| Q51760705 | A systematic review of lung-sparing extirpative surgery for pleural mesothelioma. |
| Q35832903 | Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach |
| Q38153818 | Advances in the management of pleural disease. |
| Q38800916 | Advances in treatment of mesothelioma. |
| Q34009355 | Anaesthetic management of cytoreductive surgery followed by hyperthermic intrathoracic chemotherapy perfusion |
| Q38018217 | Asbestos-related pleuropulmonary diseases: benign and malignant |
| Q55053673 | Association of malignant mesothelioma and asbestos related conditions with ovarian cancer: shared biomarkers and a possible etiological link? |
| Q37221089 | BAP1 and cancer |
| Q47734004 | BAP1 protein is a progression factor in malignant pleural mesothelioma |
| Q28387194 | Biomarkers and prognostic factors for mesothelioma |
| Q55053946 | Biomarkers in malignant mesothelioma-an unfulfilled need or a waste of resources? |
| Q38083599 | Changes in lung function after surgery for mesothelioma |
| Q44244488 | Characteristics of Malignant Pleural Mesothelioma in Women |
| Q52947737 | Chest wall resection for mesothelioma recurrence after surgery. |
| Q50050310 | Clinical and biologic prognostic factors in malignant pleural mesothelioma |
| Q48909660 | Cold-plasma coagulation in the treatment of malignant pleural mesothelioma: results of a combined approach |
| Q40688498 | Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma. |
| Q27908468 | Consensus report of the 2015 Weinman International Conference on Mesothelioma |
| Q37271498 | Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling |
| Q28393560 | Current issues in malignant pleural mesothelioma evaluation and management |
| Q38641574 | Current surgical strategies for malignant pleural mesothelioma |
| Q30371725 | Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. |
| Q92473856 | Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma |
| Q46032752 | Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma. |
| Q37090784 | Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database |
| Q36493568 | ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms |
| Q83206656 | Early mesothelioma revisited |
| Q58853910 | Effects of pneumonectomy on nitric oxide synthase expression and perivascular edema in the remaining lung of rats |
| Q43686149 | Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial |
| Q34060193 | Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma |
| Q90748160 | Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading? |
| Q34203384 | Erionite exposure in North Dakota and Turkish villages with mesothelioma. |
| Q47759752 | Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach |
| Q59137558 | Extended pleurectomy decortication: the current role |
| Q64080942 | Extra-pleural pneumonectomy |
| Q39860472 | Extra-pleural pneumonectomy in the setting of tri-modality therapy for patients with malignant pleural mesothelioma |
| Q35141809 | Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study |
| Q33871592 | Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D). |
| Q42552072 | Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach |
| Q38935100 | Extrapleural pneumonectomy for malignant pleural mesothelioma: is this an operation that should now be consigned to history? |
| Q34130373 | Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma |
| Q59137555 | Extrapleural pneumonectomy: still indicated? |
| Q35678085 | Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales |
| Q43512869 | Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma. |
| Q41441170 | Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma |
| Q47860659 | Flex-rigid pleuroscopy under local anesthesia in patients with dry pleural dissemination on radiography |
| Q37180702 | Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q28393257 | Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction |
| Q24635326 | Germline BAP1 mutations predispose to malignant mesothelioma |
| Q34194566 | Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma |
| Q28394028 | Guidelines for the diagnosis and treatment of malignant pleural mesothelioma |
| Q36901529 | HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. |
| Q41262195 | Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Toxicity and outcomes at an Australian institution |
| Q39728506 | Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma |
| Q35602502 | Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database |
| Q33877584 | Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. |
| Q40210704 | Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma. |
| Q49835562 | Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma |
| Q38809684 | Intensity-Modulated Radiation Therapy Improves the Target Coverage Over 3-D Planning While Meeting Lung Tolerance Doses for All Patients With Malignant Pleural Mesothelioma |
| Q57153508 | Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma |
| Q53586030 | Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy. |
| Q38212964 | Invasive thymoma disseminated into the pleural cavity: mid-term results of surgical resection |
| Q34293068 | Investigational approaches for mesothelioma |
| Q28395597 | Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies |
| Q38255347 | Local and systemic therapies for malignant pleural mesothelioma |
| Q57452854 | Local cancer recurrence: The realities, challenges, and opportunities for new therapies |
| Q64249092 | Long-term outcomes and quality of life should be the future focus of research measuring effectiveness of lung cancer surgery approaches |
| Q53174194 | Lung cancer: from staging to treatment - a summary of an international meeting. |
| Q37613240 | Making the case for molecular staging of malignant pleural mesothelioma |
| Q82051649 | Malignant Pleural Mesothelioma: A Population-Based Study of Survival |
| Q21202901 | Malignant mesothelioma |
| Q48514792 | Malignant mesothelioma as a difficult interdisciplinary problem. |
| Q28390539 | Malignant mesothelioma: facts, myths, and hypotheses |
| Q83412919 | Malignant pleural mesothelioma |
| Q83466825 | Malignant pleural mesothelioma |
| Q84107270 | Malignant pleural mesothelioma |
| Q64228231 | Malignant pleural mesothelioma: Is reconstruction of the diaphragm necessary in left pleurectomy/decortication? A case report |
| Q33871619 | Malignant pleural mesothelioma: adjuvant therapy with radiation therapy |
| Q34513958 | Malignant pleural mesothelioma: an update on diagnosis and treatment options |
| Q98467071 | Malignant pleural mesothelioma: between pragmatism and hope |
| Q30429528 | Malignant pleural mesothelioma: comparison of radical pleurectomy und extrapleural pneumonectomy |
| Q37217764 | Malignant pleural mesothelioma: current and future perspectives |
| Q26821919 | Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health |
| Q37866786 | Malignant pleural mesothelioma: when is radiation therapy indicated? |
| Q95360809 | Management of database: European Society of Thoracic Surgeons mesothelioma database-difficulties in improving quality data for rare tumour |
| Q85893545 | Management of malignant pleural effusion |
| Q31117531 | Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database |
| Q38215513 | Management of malignant pleural mesothelioma-The European experience |
| Q37277434 | Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). |
| Q52672887 | Medical treatment of malignant pleural mesothelioma relapses. |
| Q37866663 | Medical treatment of mesothelioma: anything new? |
| Q93381841 | Modeling Epidermal Growth Factor Inhibitor-mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture |
| Q36822118 | Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma |
| Q36599666 | Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent? |
| Q42552069 | Multimodality therapy for malignant pleural mesothelioma |
| Q53181008 | Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything? |
| Q41936079 | Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma |
| Q52581757 | New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. |
| Q26859274 | New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas |
| Q42270461 | Novel radiation therapy approaches in malignant pleural mesothelioma |
| Q40051845 | Oncolytic Viral Therapy for Mesothelioma |
| Q50048236 | Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery |
| Q33871599 | Overview of treatment related complications in malignant pleural mesothelioma |
| Q64085851 | Pain management in patients with malignant mesothelioma: challenges and solutions |
| Q64080864 | Pathological evaluation of the visceral pleura in the radical pleurectomy/decortication for malignant pleural mesothelioma patients |
| Q38792612 | Perioperative implications of thoracic decortications: a retrospective cohort study |
| Q36057453 | Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma |
| Q34747440 | Photodynamic therapy for lung cancer and malignant pleural mesothelioma. |
| Q39779237 | Photodynamic therapy for malignant pleural mesothelioma: the future of treatment? |
| Q47570332 | Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma |
| Q34274850 | Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma |
| Q40964739 | Pleurectomy and decortication |
| Q47790609 | Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study |
| Q38935087 | Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience |
| Q55022610 | Pleurectomy/decortication versus extrapleural pneumonectomy: a critical choice. |
| Q37090812 | Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery |
| Q37975136 | Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy |
| Q58758069 | Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma |
| Q45970548 | Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma. |
| Q52663125 | Progress in the Management of Malignant Pleural Mesothelioma in 2017. |
| Q64234040 | Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma |
| Q55037897 | Proton beam therapy for malignant pleural mesothelioma. |
| Q34786816 | Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication |
| Q47197708 | Radical multimodality therapy for malignant pleural mesothelioma. |
| Q35374660 | Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma |
| Q37090803 | Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools? |
| Q50200696 | Radiotherapy for the treatment of malignant pleural mesothelioma |
| Q24612464 | Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth |
| Q34142500 | Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma |
| Q40294287 | Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma |
| Q51541835 | SEOM guidelines for the treatment of malignant pleural mesothelioma. |
| Q34096881 | Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels |
| Q40070806 | Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma |
| Q37867989 | Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma |
| Q82428692 | Surgery and mesothelioma: If not randomization, at least standardization and registration! |
| Q91713578 | Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience |
| Q37762833 | Surgery for malignant pleural mesothelioma |
| Q55263507 | Surgery for malignant pleural mesothelioma: an international guidelines review. |
| Q84491850 | Surgery for mesothelioma? The debate continues |
| Q90612197 | Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma |
| Q37552639 | Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position |
| Q55018471 | Surgical Options for Malignant Mesothelioma: A Single-Center Experience. |
| Q38195607 | Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies. |
| Q30401535 | Surgical treatment of malignant pleural mesothelioma |
| Q37992694 | Systemic treatment of malignant pleural mesothelioma |
| Q35790037 | The application of cold-plasma coagulation on the visceral pleura results in a predictable depth of necrosis without fistula generation |
| Q40242222 | The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication |
| Q42019544 | The evolution of multimodality therapy for malignant pleural mesothelioma |
| Q28067111 | The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma |
| Q53136095 | The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: possible histological transformation. |
| Q38599311 | The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review |
| Q38438794 | The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence |
| Q87105218 | The use of surgery in mesothelioma |
| Q35051339 | Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma. |
| Q50050076 | Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience |
| Q55078906 | Treatment of malignant pleural mesothelioma: lessons learned and quo vadis? |
| Q36990070 | Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Grou |
| Q58103145 | Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma |
| Q45226201 | Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. |
| Q38843154 | Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations |
| Q87357879 | WITHDRAWN: Is there life after the Mesothelioma and Radical Surgery trial? Does extrapleural pneumonectomy still have a role in the management of pleural mesothelioma? A 13-year, single-center experience |
| Q36097571 | What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma? |
| Q36685838 | What is the survival after surgery for localized malignant pleural mesothelioma? |
| Q37128016 | Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy? |
| Q86613725 | [Intraoperative chemotherapy after radical pleurectomy or extrapleural pneumonectomy] |
| Q86911325 | [Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg] |
| Q86935337 | [Surgical aspects of malignant pleural mesothelioma: from the perspective of pathology] |
| Q89416570 | [Surgical therapy of malignant pleural mesothelioma] |